Halozyme Therapeutics Welcomes Jim Daly Back to Its Board of Directors

Halozyme Therapeutics Welcomes Jim Daly Back to Its Board

Halozyme Therapeutics, Inc. (Nasdaq: HALO) has recently revealed the exciting news of James "Jim" Daly’s appointment to its Board of Directors. With over thirty years of expert leadership in the biopharmaceutical sector, Daly is no stranger to driving transformative healthcare innovations.

Previously serving on the board, Daly’s return signals a strategic move for Halozyme as it looks to enhance its innovative drug delivery technologies, including its flagship ENHANZE® technology, which allows for subcutaneous delivery of biological medicines. The appointment was announced on September 30, 2026, with Halozyme’s President and CEO, Dr. Helen Torley, expressing enthusiasm about Daly’s extensive industry knowledge and experience.

Daly’s previous roles include prominent executive positions at major biopharmaceutical organizations. He was notably the Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. Prior to that, he dedicated over a decade of service at Amgen in various leadership capacities, culminating in his role as Senior Vice President for North America. His career began at Glaxo Wellcome, where he rose through the ranks for more than 16 years to eventually oversee the U.S. respiratory business.

Expressing his excitement about rejoining the board, Daly highlighted the pivotal juncture at which Halozyme stands. He referred to the company’s portfolio that includes the groundbreaking ENHANZE technology, designed to facilitate large volume subcutaneous delivery effectively. Additionally, he pointed out the importance of new innovations like Hypercon and Aerocon, which further empower at-home administration of biologics, significantly impacting patient experience and outcomes.

As he steps back into this role, Daly also serves on boards of several other biotech firms, including Acadia Pharmaceuticals, Madrigal Pharmaceuticals, and Cytokinetics, bringing a wealth of governance experience to his duties at Halozyme.

Daly holds a Bachelor of Science in Pharmacy and an MBA from the University at Buffalo, State University of New York. His strong educational background complements his vast expertise in the industry, providing Halozyme with a robust leadership element as it seeks to advance its therapeutic solutions.

Halozyme operates in a critical sector, focusing on biopharmaceutical advancements that improve patient care. The company's technology has already positively impacted over a million patients worldwide through ten unique products, found in over 100 markets. Partnering with leading corporations, such as Roche, Takeda, and Pfizer, Halozyme has established itself as a significant player in drug delivery solutions, particularly in subcutaneous administration.

The company's ongoing development programs and innovative approaches in drug-device combinations highlight its commitment to enhancing patient outcomes through convenience, reliability, and tolerability. Specifically, their commercially validated ENHANZE® solution reduces treatment burdens, ensuring that patients receive more efficient and user-friendly medical care.

In recent years, Halozyme has broadened its offerings with technologies like Hypercon™, which are set to redefine standards of drug concentration, ensuring a smoother administration process. These advancements promise to not only elevate the standards of treatment but also facilitate greater flexibility in patient healthcare settings.

In summary, Jim Daly's return to Halozyme’s Board of Directors comes at a pivotal time as the company strives to enhance its product offerings and expand its reach in the biopharmaceutical landscape. With his proven track record and strategic insight, Daly’s involvement will no doubt bolster Halozyme’s mission of improving patient experiences and outcomes in innovative therapy delivery.

For further information, visit Halozyme's website and discover more about their pioneering technologies.